For all you investors out there, remember there are three steps to getting a drug on the market in the U.S.: getting subjects enrolled in the clinical trial, meeting the trial's endpoints, and getting approved by the Food and Drug Administration. So don't jump in too early.
The trial was testing motesanib in combination with generic versions of Bristol-Myers Squibb's
The monitoring board is letting patients with non-squamous NSCLC already enrolled in the study continue, but it recommended patients with squamous NSCLC discontinue therapy because of a higher incidence of hemoptysis -- coughing or spitting up blood.
That's not particularly surprising. Genentech's
The safety board will review more data in three months, but things certainly aren't looking up for Amgen and Takeda at the moment. The duo is also testing motesanib in breast cancer, but don't use the above to predict the success rate for that. There are plenty of examples of drugs that work for one cancer type, but not others. For instance, Nexavar is used for liver and kidney cancer while Avastin is approved for colon cancer and non-squamous NSCLC.
Lung cancer is a hard disease to fight -- just ask AstraZeneca
Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.